R&D News | pharmaphorum

News

Advantage Novo Nordisk in battle of weight-loss drugs

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in

News

Astellas adds to cell therapy drive with Poseida deal

Astellas has added another programme to its growing cell therapy pipeline via an agreement with Poseida on an off-the-shelf CAR-T therapy for solid tumours.

News

Nektar says Lilly got it wrong on eczema drug rezpeg

Nektar Therapeutics says that Eli Lilly made a big mistake when it reported data on a pair of phase 1b trials of its rezpegaldesleukin drug in atopic dermatitis and psoria

News

Bavarian Nordic preps chikungunya vaccine filings

Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph

News

Biotech investment in UK ticks up in Q2

Despite the economic downturn, UK life sciences companies raised a healthy £382 million ($486 million) in new financing in the second quarter of the year, with venture cap

News

UK opens '100-day' rapid-response vaccine unit

The UK government has formally opened a state-of-the-art vaccine research facility based at the UK Health and Security Agency (UKHSA) to improve the country's preparedness

Advantage Novo Nordisk in battle of weight-loss drugs

Astellas adds to cell therapy drive with Poseida deal

Nektar says Lilly got it wrong on eczema drug rezpeg

Bavarian Nordic preps chikungunya vaccine filings

Biotech investment in UK ticks up in Q2

UK opens '100-day' rapid-response vaccine unit

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks